Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“BCG pretreated NMIBC is moving fast in the USA with rapid FDA approvals from single arm trials.
The drugs look active but ‘rapid’ study design creates uncertainty.
Europe is going in a different direction, both can’t be right?”
More posts featuring Tom Powles